Abstract:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs), harboring spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) mutations, exhibit reduced in vitro susceptibility to convalescent-phase serum, commercial antibody cocktails, and vaccine neutralization and have been associated with reinfections. The accumulation of these mutations could be the consequence of intrahost viral evolution due to prolonged infection in immunocompromised hosts. In this study, we document the microevolution of SARS-CoV-2 recovered from sequential tracheal aspirates from an immunosuppressed patient on steroids and convalescent plasma therapy and identify the emergence of multiple NTD and RBD mutations. SARS-CoV-2 genomes from the first swab (day 0) and from three tracheal aspirates (days 7, 21, and 27) were compared at the sequence level. We identified a mixed viral population with five different S protein mutations (141 to 144 deletion, 243 to 244 deletion, E484K, Q493K, and Q493R) at the NTD or RBD region from the second tracheal aspirate sample (day 21) and a predominance of the S protein 141 to 144 LGVY deletion and E484K mutant on day 27. The neutralizing antibodies against various S protein lentiviral pseudovirus mutants, as well as the anti-SARS-CoV-2 total Ig and IgG, showed "U" shape dynamics, in support of the endogenous development of neutralizing antibodies. The patient's compromised immune status, the antirejection regiment, convalescent plasma treatment, and the development of neutralizing antibodies may have resulted in unique selective pressures on the intrahost genomic evolution, and this observation supports the hypotheses that VOCs can independently arise and that immunocompromised patients on convalescent plasma therapy are potential breeding grounds for immune escape mutants. IMPORTANCE Over a year of the COVID-19 pandemic, distinct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) lineages have arisen in multiple geographic areas around the world. SARS-CoV-2 variants of concern (VOCs), i.e., B.1.1.7 (alpha), B.1.351 (beta), P.1 (gamma), and B.1.617.2 (delta), harboring mutations and/or deletions in spike protein N-terminal domain (NTD) or receptor-binding domain (RBD) regions showed evidence of increased transmissibility and disease severity and possible reduced vaccine efficacy. In this study, we report the emergence of five different NTD and RBD mutations in an uncommon SARS-CoV-2 B.1.369 lineage from an immunosuppressed patient undergoing steroid and convalescent plasma therapy. The observation highlighted that VOCs can independently arise in immunocompromised populations undergoing anti-SARS-CoV-2 therapy, and enhanced measures will be required to reduce the transmission.

Delta-Omicron Recombinant Escapes Therapeutic Antibody Neutralization

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

A human monoclonal antibody neutralizing SARS-CoV-2 Omicron variants containing the L452R mutation

Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants

Neutralization of SARS-CoV-2 Omicron BA.2 by Therapeutic Monoclonal Antibodies.

Recombination Events Among SARS-CoV-2 Omicron Subvariants: Impact on Spike Interaction With ACE2 Receptor and Neutralizing Antibodies

Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants

Novel Monoclonal Antibodies and Recombined Antibodies Against Variant SARS-CoV-2

Neutralization, effector function and immune imprinting of Omicron variants

Considerable escape of SARS-CoV-2 Omicron to antibody neutralization

Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment

B.1.1.529 escapes the majority of SARS-CoV-2 neutralizing antibodies of diverse epitopes

Emerging variants develop total escape from potent monoclonal antibodies induced by BA.4/5 infection

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies

Differential Escape of Neutralizing Antibodies by SARS-CoV-2 Omicron and Pre-Emergent Sarbecoviruses

Antibody evasion properties of SARS-CoV-2 Omicron sublineages

Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations

A SARS-CoV-2 Antibody Retains Potent Neutralization Against Omicron by Targeting Conserved RBM Residues

SARS-COV-2 Omicron variants conformationally escape a rare quaternary antibody binding mode

Recombinant SARS-CoV-2 Delta/Omicron BA.5 emerging in an immunocompromised long-term infected COVID-19 patient

Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains